Palvella Therapeutics, Inc. (PVLA)
| Market Cap | 2.11B +119.0% |
| Revenue (ttm) | n/a |
| Net Income | -74.99M |
| EPS | -5.57 |
| Shares Out | 14.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 312,469 |
| Open | 152.50 |
| Previous Close | 152.48 |
| Day's Range | 143.31 - 157.00 |
| 52-Week Range | 72.23 - 179.95 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 233.44 (+61.44%) |
| Earnings Date | Nov 5, 2026 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for PVLA stock is "Strong Buy." The 12-month stock price target is $233.44, which is an increase of 61.44% from the latest price.
News
Leerink bullish on Palvella Therapeutics, initiates with an Outperform
As previously reported, Leerink initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $228 price target The firm believes the investment case centers on 3 debates, namely wh...
Palvella Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $228 price target
Palvella Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
Priority review sets a February 28, 2027 PDUFA date for QTORIN rapamycin in mLM, while launch preparation and center outreach advance. Pipeline plans include cVM Phase III before year-end 2026 and an angiokeratoma readout in H2 2027.
Palvella Therapeutics price target raised to $243 from $232 at Canaccord
Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $243 from $232 and keeps a Buy rating on the shares. The fdirm updated its model following Q3 results…
Palvella Therapeutics price target raised to $230 from $226 at Raymond James
Raymond James raised the firm’s price target on Palvella Therapeutics (PVLA) to $230 from $226 and keeps a Strong Buy rating on the shares. Palvella continues to advance QTORIN toward…
Palvella Therapeutics price target raised to $230 from $205 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Palvella Therapeutics (PVLA) to $230 from $205 and keeps a Buy rating on the shares. The firm cites a high likelihood of Qtorin…
Palvella Therapeutics price target raised to $232 from $210 at Oppenheimer
Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $232 from $210 and keeps an Outperform rating on the shares. Alongside Q3 results, Palvella detailed commercial preparatio...
Palvella Therapeutics reports Q3 EPS ($1.70), consensus ($1.73)
“I’m pleased to share that Verisk delivered third-quarter financial results that returned to levels in line with our annual Investor Day targets and reflect the continued sequential acceleration in gr...
Palvella Therapeutics Earnings Call Transcript: Q3 2026
FDA accepted the QTORIN rapamycin mLM NDA for Priority Review, with a February 28, 2027 PDUFA date. Q3-end cash was $236.7M, which management expects to fund launch and pipeline programs.
Palvella Therapeutics Earnings release: Q3 2026
Palvella Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Palvella Therapeutics Quarterly report: Q3 2026
Palvella Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Palvella Therapeutics Slides: Q3 2026
Palvella Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
WAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializi...
Palvella Therapeutics price target lowered to $232 from $240 at Mizuho
Mizuho lowered the firm’s price target on Palvella Therapeutics (PVLA) to $232 from $240 and keeps an Outperform rating on the shares.
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializ...
Palvella Therapeutics announces FDA acceptance, priority review for Qtorin NDA
Palvella Therapeutics (PVLA) announced that the FDA has accepted for filing and granted Priority Review to the company’s new drug application, or NDA, for Qtorin 3.9% rapamycin anhydrous gel for…
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and a...
Clear Street sees positive read for Palvella from FDA rare disease framework
Noting that the FDA launched its Rare Disease Framework Initiative on October 14, Clear Street sees “meaningful positive readthrough” for Palvella Therapeutics (PVLA) as the framework’s stated princip...
Palvella Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
QTORIN rapamycin is progressing toward a potential H1 next-year FDA decision and commercial launch, with MLM and CVM representing an estimated $1 billion-$3 billion peak-sales opportunity. Additional trials and two disease-program announcements are planned by year-end.
Raymond James says new data supportive of broad label for Qtorin
Raymond James analyst Ryan Deschner keeps a Strong Buy rating on Palvella Therapeutics (PVLA) announced yesterday morning the presentations of two posters highlighting new pediatric subgroup analyses ...
Palvella Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating. Palvella is a rare disease company that takes drugs already known to work and reformulates them with its…
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializi...
Palvella Therapeutics price target lowered to $246 from $270 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Palvella Therapeutics (PVLA) to $246 from $270 and keeps a Buy rating on the shares. The firm updated the company’s model to…